Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms [68Ga]Ga-PentixaFor, Gallium (68Ga) boclatixafortide, PentixaFor + [3] |
Target |
Action antagonists |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Marginal Zone B-Cell Lymphoma | Phase 3 | Austria | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | France | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | Germany | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | Italy | 20 May 2024 | |
Marginal Zone B-Cell Lymphoma | Phase 3 | Spain | 20 May 2024 | |
Hyperaldosteronism | Phase 3 | - | - | |
Primary Central Nervous System Lymphoma | Phase 2 | Denmark | 05 Oct 2022 | |
Primary Central Nervous System Lymphoma | Phase 2 | France | 05 Oct 2022 | |
Secondary Central Nervous System Lymphoma | Phase 2 | Denmark | 05 Oct 2022 | |
Secondary Central Nervous System Lymphoma | Phase 2 | France | 05 Oct 2022 |
Not Applicable | - | (Single PET model) | xoeaphrmfi(toyphjqahn) = xerzkgbqti pggdczdeyi (ymlnomlgob ) | Positive | 27 Sep 2024 | ||
Not Applicable | Soft Tissue Infections CXCR4 receptors | 20 | Ga-Pentixafor (Chronic periprosthetic infections (PPI)) | udgyqjcwed(pgiuludvsb) = kurcfjxder nqgefobndm (ruieychhem ) View more | Positive | 27 Sep 2024 | |
Ga-Pentixafor (Diabetic foot infections (DFI)) | udgyqjcwed(pgiuludvsb) = lyvspsrpaw nqgefobndm (ruieychhem ) View more | ||||||
Not Applicable | 30 | (68Ga-Pentixafor PET/CT) | zoxwslugem(ogpjxqzwlv) = bjhukmmyeg phfwaepzop (sagaeyaxcy ) View more | - | 01 Jun 2024 | ||
(Adrenal vein sampling (AVS)) | zoxwslugem(ogpjxqzwlv) = cahysbhhuy phfwaepzop (sagaeyaxcy ) View more | ||||||
Not Applicable | - | (Aldosterone-producing adenoma (APA)) | icfddpcenp(fxcnyksyvq) = rjoavnpykl hwerkjhoug (vkoyiwuivo ) View more | - | 21 Dec 2023 | ||
(Idiopathic hyperaldosteronism (IHA)) | dwnbhiabqv(goffwhybxt) = crapctpxvr iammlnrmrv (bebexddlvw ) | ||||||
Not Applicable | - | (18F-FDG PET/CT) | wxmiobebje(fjhypfsbbv) = rsnyqaztrp mbffcbblsz (dvbphcasmp ) View more | - | 28 Aug 2023 | ||
Not Applicable | - | CXCR4-directed PET/CT (Cancer patients imaged with CXCR4-targeted PET/CT using [68Ga]PentixaFor) | vxeodqubqu(evzkzxnymh) = ldzrgudsju ufevonikcv (vpuykjmqhe ) View more | - | 28 Aug 2023 | ||
Phase 1 | 19 | (AVS) | pecljczjnp(gszfmnpank) = boylnydubp vmcuqfxgbu (ohxbakpwlv ) | - | 01 Jun 2023 | ||
Not Applicable | - | (Functional nodules in primary aldosteronism) | bwyenkrmdy(vrwoobdqwn) = 8.95 mhcccpekbv (yyllhzaccb ) View more | - | 07 Sep 2022 | ||
(Non-functional adrenal adenoma) | |||||||
Not Applicable | - | (68Ga-Pentixafor PET/CT) | pvzsxdgvnr(iehexfxrdq) = kfuesizrwh gwslykutji (xkadcaffbo, 12.1 - 16.4) | - | 08 Aug 2022 | ||
Not Applicable | - | (68Ga-Pentixafor) | eczoobbwqf(hmonjkgciz) = onmnntcdcc mehdxbqrdw (zuapmtlmwj, 0.64) | - | 18 May 2021 |